News for hackers. Stuff that matters.
Re:Goldman Sachs questions whether curing patients is a sust... by ekianjo on Friday April 13, 2018 @08:26AM (#16829294)
This is wishful thinking because you never know ahead of time what is going to work and certainly not the pharmacodynamics of your drug. Plus your reasonning is false, even with current chronic conditions like RA many companies are exploring different dosages of bio treatments to drive remission instead of lifetime treatment.

There are no comments on this comment yet.